Ngokusho kukaJabbar et al. EYunivesithi yaseGothenburg eSweden, i-mass spectrometry ehlosiwe esuselwa kuma-biomarker amathathu kuphela we-cyst fluid angakwazi ukubona nokuhlola ngokunembile kungenzeka kwe ama-cyst pancreatic akhula abe umdlavuza pancreatic . Kuyafaneleka ukwenza ezinye izifundo zokuqinisekisa ukuthi le ndlela yokuhlola ingasiza yini ekuxilongeni umdlavuza kusenesikhathi, ingenelele ngempumelelo futhi ivimbele umdlavuza. (J Clin Oncol. Inguqulo ye-inthanethi kaNovemba 22, 2017)
Cystic lesions of the pancreas are very common in imaging, and about half are umdlavuza pancreatic lesions. Therefore, accurate and specific diagnosis is essential for the correct treatment of patients. Unfortunately, the currently used diagnostic methods cannot effectively distinguish between pancreatic precancerous lesions and malignant pancreatic cystic lesions.
Abaphenyi basebenzise amasampula e-cystic fluid atholakala ngokugqobhoza ngaphansi kokuqondiswa kwe-endoscopy ejwayelekile ye-ultrasound ukuze ihlaziywe. Esifundweni seqembu leziguli ezingama-24, indlela yokuhlola amaprotheni biology ikhombe ama-biomarker angama-8 anganikeza imininingwane ngoshintsho olubi kanye nezinguquko ezisezingeni eliphezulu ze-dysplasia / umdlavuza. Ngemuva kwalokho, ukuhlaziywa kwamanani ama-peptide anelebula angama-30 kanye nokuqapha okufanayo kwe-mass reaction okwenziwa kwiziguli ezingama-80 kusethi yedatha neziguli ezingama-68 kusethi yokuqinisekisa. Iphuzu lokugcina locwaningo laliwumphumela wokuxilongwa kwe-pathology yokuhlinzwa noma ukulandelwa komtholampilo.
The results show that the best markers for malignant tumors may be a group of peptides derived from MUC-5AC and MUC-2. These markers can identify precancerous lesions / malignant lesions from benign lesions. The accuracy is as high as 97%. Compared with the cystic liquid carcinoembryonic antigen and cytological detection of these standard identification methods, the accuracy of these standard methods is 61% (95% CI 46% ~ 74%, P <0.001) and 84% (95% CI 71% ~ 92%, P = 0.02). MUC-5AC combined with prostate stem cell antigen can identify high-grade dysplasia or cancer, with an accuracy of 96%, can detect 95% of malignant lesions or severe dysplasia, and the detection rate of carcinoembryonic antigen and cytology 35% and 50% respectively (P <0.001, P = 0.003).
